Mutant NRAS was associated with a superior OS both in patients with IR‐AML (2‐year OS: 76.4% vs 48.7%, P = .014) (Figure S4G) and in CN‐AML (2‐year OS: 100% vs 51.0%, P = .010) (Figure S4H). The gene discussed is NRAS; the disease is acute myeloid leukemia.